Westlake Longevity Cohort (We-Longevity)

December 5, 2023 updated by: Westlake University
The Westlake Longevity Cohort (We-Longevity) is a prospective cohort study among centenarians, nonagenarians, senior citizens and their family members up to three generations living in Lishui, China. The primary aim of this cohort is to characterize the multi-omics molecular characteristics of healthy longevity and their dynamic trajectories. Another aim of We-Longevity is to investigate the association of dietary and lifestyle with the multi-omics molecular characteristics of healthy longevity, and to facilitate the development of personalized nutritional/lifestyle recommendation for the public.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Aging is a major risk factor for most fatal diseases, such as Alzheimer's disease, type 2 diabetes, cardiovascular disease and cancer. Global population aging is becoming increasingly serious, and this trend is mainly driving the annual increase in the prevalence of aging-related diseases. Healthy longevity are influenced by a variety of factors, such as diet structure, lifestyle, ecological environment, gut microbiome and genetics. At present, the researches on healthy longevity are mainly focused on Drosophila, nematodes and mouse models, and few studies on longevity population. Centenarians and nonagenarians are the best objects to study healthy longevity. However, the multi-omics molecular characteristics and regulatory mechanism of healthy longevity in human are still unclear. There, the present We-Longevity design includes 200 centenarians, 600 nonagenarians, 400 senior citizens. We will determine the fecal/serum metabolome, gut microbiome serum proteome and genome, together with diet, lifestyle and disease information.

Study Type

Observational

Enrollment (Estimated)

1200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Zhejiang
      • Lishui, Zhejiang, China, 323000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

All the participants should be Chinese residents, regardless of the ethics.

Description

Inclusion Criteria:

  • Participants aged 50 years or order.
  • Participants live in Lishui, China.
  • Participants intend to remain in Lishui for ≥3 years.

Exclusion Criteria:

  • Participants with cancer, serious medical disorders or infectious diseases.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gut microbiota
Time Frame: 36 months
Fecal microbiome will be analyzed by 16S rRNA gene sequencing and metagenome sequencing.
36 months
aging
Time Frame: 36 months
Physical frailty will be evaluated by using Fried's criteria.
36 months
Metabolomics of serum and gut microbiome
Time Frame: 36 months
Metabolomics of serum and gut microbiome will be analyzed by liquid chromatograph-mass spectrometer (LC/MS).
36 months
Proteomic profiling of serum
Time Frame: 36 months
Proteomic characterization of serum will be analyzed by liquid chromatograph-mass spectrometer (LC/MS).
36 months
Genome
Time Frame: 36 months
Genomic characterization will be analyzed by Illumina ASA-750K arrays.
36 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive function
Time Frame: 36 months
Cognitive function will be evaluated by using Mini-Mental State Examination (MMSE).
36 months
Blood glucose examination of blood samples
Time Frame: 36 months
Blood glucose will be analyzed by automatic biochemical analyser.
36 months
Blood blood lipids examination of blood samples
Time Frame: 36 months
Blood blood lipids (HDL, LDL, TC and TG) will be analyzed by automatic biochemical analyser.
36 months
Serum cytokines examination of blood samples
Time Frame: 36 months
Serum cytokines (IFNγ, IL10, IL12p70, IL13, IL1β, IL2, IL4, IL6, IL8 and TNFα) will be analyzed by electrochemiluminescence immunoassay.
36 months
Serum neurotranszmitters examination of blood samples
Time Frame: 36 months
Serum neurotranszmitters (dopamine, choline, acetyl choline, tyramine, tryptamine, 5-hydroxyindoleacetic acid, phenylpyruvic acid, 3,4-dihydroxyphenylacetic acid and 3-hydroxyo-aminobenzoic acid) will be analyzed by liquid chromatograph-mass spectrometer (LC/MS).
36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Westlake University

Collaborators

The Sixth Affiliated Hospital of Wenzhou Medical University

Investigators

  • Principal Investigator: Ju-Sheng Zheng, PhD, Westlake University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 15, 2021

Primary Completion (Estimated)

November 14, 2025

Study Completion (Estimated)

November 14, 2031

Study Registration Dates

First Submitted

November 15, 2021

First Submitted That Met QC Criteria

February 21, 2022

First Posted (Actual)

February 25, 2022

Study Record Updates

Last Update Posted (Estimated)

December 12, 2023

Last Update Submitted That Met QC Criteria

December 5, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20211015ZJS001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neurodegenerative Diseases

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe